HIV-1 vaccines and adaptive trial designs.

New paradigms for HIV/AIDS vaccine development. Annu Rev Med (2011) 2.21

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol (2015) 1.70

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A (2014) 1.39

Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med (2015) 1.30

Designing tomorrow's vaccines. N Engl J Med (2013) 1.21

Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05

Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01

Location and dynamics of the immunodominant CD8 T cell response to SIVΔnef immunization and SIVmac251 vaginal challenge. PLoS One (2013) 0.99

Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials (2014) 0.93

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine (2015) 0.92

Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res Hum Retroviruses (2011) 0.90

Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool. Immunol Rev (2015) 0.86

Vaccine design: emerging concepts and renewed optimism. Curr Opin Biotechnol (2013) 0.84

Drug versus vaccine investment: a modelled comparison of economic incentives. Cost Eff Resour Alloc (2013) 0.84

HIV vaccine development: strategies for preclinical and clinical investigation. AIDS Res Hum Retroviruses (2013) 0.84

A systems framework for vaccine design. Curr Opin Immunol (2013) 0.83

Roadblocks to translational challenges on viral pathogenesis. Nat Med (2013) 0.82

New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS (2013) 0.80

Lessons learned from HIV vaccine clinical efficacy trials. Curr HIV Res (2013) 0.79

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol (2016) 0.78

Is an HIV vaccine possible? J Acquir Immune Defic Syndr (2012) 0.78

Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clin Investig (Lond) (2012) 0.76

HIV-1 prophylactic vaccines: state of the art. J Virus Erad (2016) 0.75

Overcoming research barriers in Chagas disease-designing effective implementation science. Parasitol Res (2016) 0.75

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65

A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis (2005) 1.70

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med (2010) 1.53

Adaptive clinical trials: progress and challenges. Drugs R D (2008) 1.37

Philosophy of science. The coordinates of truth. Science (2009) 1.18

Issues in the use of adaptive clinical trial designs. Stat Med (2006) 1.02

DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79

Identifying biological themes within lists of genes with EASE. Genome Biol (2003) 31.72

Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38

DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res (2007) 17.46

HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A (2002) 17.22

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol (2007) 16.46

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61

A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72

DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics (2007) 12.76

Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis (2008) 11.01

Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69

HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30

DAVID gene ID conversion tool. Bioinformation (2008) 9.16

The challenge of emerging and re-emerging infectious diseases. Nature (2004) 8.94

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92

Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med (2009) 7.33

Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr (2003) 7.23

Universal voluntary testing and treatment for prevention of HIV transmission. JAMA (2009) 7.20

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med (2005) 7.18

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Development and homeostasis of T cell memory in rhesus macaque. J Immunol (2002) 6.88

Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06

The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35

T cell dynamics in HIV-1 infection. Annu Rev Immunol (2001) 5.29

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol (2008) 5.24

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22

Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13

HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01

The 1918 influenza pandemic: insights for the 21st century. J Infect Dis (2007) 4.99

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86

Acute HIV-1 Infection. N Engl J Med (2011) 4.84

Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79

B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73

Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68

Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis (2008) 4.47

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35

Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood (2003) 4.24

Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med (2006) 4.23

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06

HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A (2005) 4.02

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90

The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis (2008) 3.84

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82

An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78

CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med (2004) 3.78

The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72

High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68

Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology (2012) 3.63

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62

The persistent legacy of the 1918 influenza virus. N Engl J Med (2009) 3.58

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50

Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47

Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40

The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol (2007) 3.38

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32

Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science (2010) 3.31

HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30

Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27

A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26

Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24